West Michigan Advisors LLC Invests $300,000 in Sanofi $SNY

West Michigan Advisors LLC acquired a new stake in Sanofi (NASDAQ:SNY) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 6,210 shares of the company’s stock, valued at approximately $300,000.

Several other hedge funds have also recently bought and sold shares of the company. R Squared Ltd purchased a new position in Sanofi in the 2nd quarter valued at approximately $435,000. Bleakley Financial Group LLC increased its stake in Sanofi by 3.4% in the 2nd quarter. Bleakley Financial Group LLC now owns 117,680 shares of the company’s stock valued at $5,685,000 after purchasing an additional 3,890 shares in the last quarter. RNC Capital Management LLC increased its position in Sanofi by 12.7% during the second quarter. RNC Capital Management LLC now owns 6,883 shares of the company’s stock worth $333,000 after buying an additional 775 shares in the last quarter. Exencial Wealth Advisors LLC increased its position in Sanofi by 5.0% during the second quarter. Exencial Wealth Advisors LLC now owns 63,446 shares of the company’s stock worth $3,065,000 after buying an additional 2,994 shares in the last quarter. Finally, Whittier Trust Co. increased its position in Sanofi by 34.1% during the second quarter. Whittier Trust Co. now owns 1,462 shares of the company’s stock worth $71,000 after buying an additional 372 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on SNY. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Finally, Barclays restated an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $62.67.

Sanofi Price Performance

Shares of Sanofi stock opened at $51.64 on Friday. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The stock has a market capitalization of $126.80 billion, a P/E ratio of 12.41, a PEG ratio of 1.20 and a beta of 0.51. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The business’s fifty day moving average price is $48.65 and its 200 day moving average price is $49.55.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the previous year, the business posted $1.73 EPS. Sanofi’s revenue was down 7.0% compared to the same quarter last year. As a group, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.